Appointment Type |
Department |
Division |
Rank |
Primary |
Med - Infectious Diseases |
Med - Infectious Diseases |
Professor |
Center |
Center for Outcomes & Effectiveness Res & Educ |
Center for Outcomes & Effectiveness Res & Educ |
Professor |
|
Publication |
PUBMEDID |
Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-678. |
|
Chapman SW, Bradsher RW, Campbell DG, Pappas PG, Kauffman CA. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 2000; 30:679-683. |
|
Saag MS, Graybill JR, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE for the Mycoses Study Group Cryptococcal Subproject. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30:710-718. |
|
Baddley JW, Pappas PG. Cryptococcosis. Curr Opin Inf Dis 2000; 2:525-533. |
|
Baddley JW, Smith AM, Moser SA, Pappas PG. Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a University Hospital. Diag Micro Infect Dis 2001;39:199-201. |
|
Baddley JW, Stroud TP, Salzman D, and Pappas PG. Invasive mould infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-1324. |
|
Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, Henderson H, Kauffman CA, Haas DW, Saccente M, Hamill RJ, Holloway MS, Warren RM, Dismukes WE. Cryptococcosis in HIV-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690-699. |
|
Pappas PG. Therapy of cryptococcal meningitis in non-HIV-infected patients. Current Infectious Disease Reports 2001;3:365-370. |
|
Donowitz GR, Maki DG, Pappas PG, Rolston K. Infection in the neutropenic patient-new views of an old problem. Hematology 2001;93-119. |
|
Walsh TJ, Goodman JL, Pappas PG, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45:3487-3496. |
|
|
|